HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+1.1%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$800M
AUM Growth
+$800M
(-18%)
Cap. Flow
-$190M
Cap. Flow
% of AUM
-23.8%
Top 10 Holdings %
Top 10 Hldgs %
45.64%
Holding
74
New
18
Increased
11
Reduced
22
Closed
14
Top Buys
| 1 |
AbbVie
ABBV
|
$41.6M |
| 2 |
Thermo Fisher Scientific
TMO
|
$26M |
| 3 |
Agilent Technologies
A
|
$24.3M |
| 4 |
Amgen
AMGN
|
$17M |
| 5 |
DexCom
DXCM
|
$14.4M |
Top Sells
| 1 |
Biogen
BIIB
|
$91.8M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$41.7M |
| 3 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$36.5M |
| 4 |
Natera
NTRA
|
$36.5M |
| 5 |
Boston Scientific
BSX
|
$32.9M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$11.2B
| $64.3M | 8.05% | 759,038 +18,090 | +2% | +$1.53M |
|
|
2
AbbVie
ABBV
$372B
| $41.6M | 5.21% | +310,250 | New | +$41.6M |
|
|
3
Agilent Technologies
A
$35.7B
| $41.1M | 5.14% | 338,030 +199,750 | +144% | +$24.3M |
|
|
4
Boston Scientific
BSX
$156B
| $37.1M | 4.64% | 958,600 -849,390 | -47% | -$32.9M |
|
5
Eli Lilly
LLY
$657B
| $33.4M | 4.17% | 103,150 +32,520 | +46% | +$10.5M |
|
6
Cencora
COR
$56.5B
| $32.4M | 4.05% | 239,150 +82,240 | +52% | +$11.1M |
|
7
UnitedHealth
UNH
$281B
| $31.8M | 3.98% | 62,980 -5,250 | -8% | -$2.65M |
|
8
Danaher
DHR
$147B
| $30.4M | 3.81% | 117,800 +20,920 | +22% | +$5.4M |
|
9
Tenet Healthcare
THC
$16.3B
| $26.8M | 3.35% | 518,990 | – | – |
|
|
10
Thermo Fisher Scientific
TMO
$186B
| $26M | 3.25% | +51,240 | New | +$26M |
|
11
Centene
CNC
$14.3B
| $23.4M | 2.93% | 300,970 -239,890 | -44% | -$18.7M |
|
12
Cigna
CI
$80.3B
| $21.3M | 2.67% | 76,910 -19,560 | -20% | -$5.43M |
|
13
Cytokinetics
CYTK
$4.23B
| $21.1M | 2.63% | 434,560 -51,040 | -11% | -$2.47M |
|
14
Humana
HUM
$36.5B
| $20.8M | 2.6% | 42,920 -4,300 | -9% | -$2.09M |
|
15
Syndax Pharmaceuticals
SNDX
$1.41B
| $20.6M | 2.58% | 859,240 -64,160 | -7% | -$1.54M |
|
|
16
DexCom
DXCM
$29.5B
| $20.4M | 2.55% | 253,500 +178,720 | +239% | +$14.4M |
|
|
17
Biogen
BIIB
$19.4B
| $18.7M | 2.34% | 69,950 -343,690 | -83% | -$91.8M |
|
18
Elevance Health
ELV
$71.8B
| $17.7M | 2.21% | 38,910 -15,320 | -28% | -$6.96M |
|
|
19
Amgen
AMGN
$155B
| $17M | 2.12% | +75,370 | New | +$17M |
|
20
LivaNova
LIVN
$3.08B
| $16.7M | 2.08% | 328,030 -158,520 | -33% | -$8.05M |
|
21
Henry Schein
HSIC
$8.44B
| $16.4M | 2.05% | 248,920 | – | – |
|
22
Bristol-Myers Squibb
BMY
$96B
| $15.9M | 1.98% | 223,150 -189,270 | -46% | -$13.5M |
|
23
Incyte
INCY
$16.5B
| $15.2M | 1.9% | 227,851 -6,279 | -3% | -$418K |
|
|
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.2M | 1.78% | 229,530 -674,320 | -75% | -$41.7M |
|
25
Becton Dickinson
BDX
$55.3B
| $14M | 1.75% | 62,930 +7,220 | +13% | +$1.61M |
|